Larry Bock

We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

San Diego-based Sapphire Energy is pioneering an approach that takes two very old processes and synthesizes them into one very new opportunity. Farming and algae have been around for most of human existence, but the two have not been paired in any significant way to bring leverage the positive effects on one another. Sapphire’s products and processes in this category differ significantly from others because they are made solely from photosynthetic microorganisms (algae and cyanobacteria), using sunlight and CO2 as their feedstock; are not dependent on food crops or valuable farmland; do not use potable water; do not result in biodiesel or ethanol; are compatible with existing infrastructure; and are low carbon, renewable and scalable. Sapphire has an R&D facility in Las Cruces, New Mexico, and has been operating a 300-acre facility continuously since May 1, 2012. Learn More at www.sapphireenergy.com Like us on Facebook https://www.facebook.com/Sapphireenergy Follow us on twitter https://twitter.com/SapphireEnergy Watch our videos https://www.youtube.com/user/SapphireEnergyVideo

Siluria Technologies is pioneering the commercial production of fuels and chemicals made from clean, abundant natural gas. Siluria’s break through Oxidative Coupling of Methane ("OCM"​) process technology is believed to be the first commercially viable process to directly convert methane to ethylene. Siluria’s second process technology can convert ethylene to liquid fuels such as gasoline, diesel or jet fuel. This enables natural gas to potentially supplement petroleum as the worldwide basis for transportation fuels and commodity chemicals. Siluria’s revolutionary catalyst and process technologies uniquely combine nanomaterials, templating and chemical engineering, to convert natural gas into higher value products using efficient processes that can be seamlessly integrated into existing industry infrastructure. Siluria has assembled a world-class team of management, analysts, scientists and engineers. We are always on the lookout for talented individuals who are looking to contribute to groundbreaking R&D and engineering innovations in the energy industry. If you are interested in working with Siluria please visit our career’s page at: https://www.theapplicantmanager.com/careers?co=si. You are welcome to submit your resume even If no positions (of interest to you) are posted but please note that we will only accept and consider applications submitted through our career’s page. If you are a recruiter and interested in working with Siluria Technologies, please contact our HR Director. Siluria does not accept unsolicited resumes submitted by recruiters and/or recruiting companies. Equal Employment Opportunity: Siluria Technologies Inc. is an Equal Employment Opportunity employer - Minorities/Female/Veterans/Disabled.  Our Company provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, genetics, disability or protected veteran status.  In addition to federal law requirements, Siluria complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities.  It is the policy of Siluria Technologies, Inc. to take voluntary, positive action in providing affirmative action and equal employment opportunity to individuals with disabilities and protected veterans. All personnel actions, including compensation, benefits, recruitment, hiring, training, and promoting persons in all job titles, will be administered without regard to disability or protected veteran status, and all employment decisions are based solely on valid job requirements.  A copy of our Equal Employment Opportunity statement which reaffirms our commitment to qualified individuals with disabilities and protected veterans is posted at: http://www.siluria.com/admin/kcfinder/upload/files/Siluria%20Technologies%20EEO%20Policy%202017.pdf. Should an employee or applicant request the policy be made available in an alternative format that is accessible and understandable to them, it shall be provided. 

ZOZI's mission is to provide best-in-class online booking software for tour and activity businesses. We inspire people to Get Out There™ and experience the world. For tour, activity, rental and event businesses, ZOZI Advance is the fastest growing online reservation, payment and customer management software used by thousands of businesses across nearly 90 countries. For people who crave new experiences, our online marketplace at ZOZI.com helps them discover and book thousands of activities and travel getaways, and find inspiring stories on exploration & discovery—both locally and far away. Five million people have used ZOZI to discover and book things to do around the globe, purchasing nearly a billion dollars in activities. ZOZI is headquartered in San Francisco, with offices in Vancouver, CA. Investors include Virgin Group founder Sir Richard Branson and Pritzker Vlock Ventures. Learn about our leading online booking software at www.zozi.com/advance. Book experiences at www.zozi.com. #LiveZOZI

Cambrios is the leader in silver nanowire solutions to enable the development of electronic devices with transparent conductors. Our proprietary nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components at lower manufacturing cost. ClearOhm™, our first product, is a directly patternable, wet-processable transparent conductive film made from silver nanowires that is poised to replace the industry standard sputtered indium tin oxide (ITO). Subsequent products will leverage this technology to produce other functional films for display and thin film applications for multiple consumer electronic device markets.

Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com

Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikon’s platform enables the design of highly selective and targeted medicines, supporting the company’s broader strategy to develop personalized medicines. In 2005, Plexxikon scientists discovered ZELBORAF® (vemurafenib) tablets, formerly known as PLX4032, and initiated the first clinical trial in 2006. Together with its partner Roche, Plexxikon co-developed this mutation-specific medicine, in less than five years. A companion diagnostic used to determine ZELBORAF treatment eligibility was approved at the same time. ZELBORAF has been approved in over 40 countries worldwide. Plexxikon's demonstrated capability in discovery and early development, as well as its diverse pipeline, uniquely positions the company to develop multiple commercial franchises for different therapeutic indications, and create significant value for Plexxikon and its collaborators. Plexxikon's novel discovery approach, combined with an experienced management and scientific team, a broad network of scientific and clinical experts, and partnerships that support later stage development, have been key drivers of the company's success since it began operations in 2001.

Fast Track works with major brands and Governing Bodies to develop and implement strategies that drive business through sport. We are one of the fastest growing International sports marketing agencies with offices in Europe, Middle East, Asia and Australasia. Established in 1998 with one client, today we represent over 40 clients across 100 sponsorships covering major global, regional and national sports events as well as a variety of developing sports and youth engagement programmes. Fast Track is part of leading marketing services group, Chime Communications which comprises a network of 50 agencies and over 1,100 people. www.chime.plc.uk/ We recognise that every client is unique and requires different solutions but all share one common goal: to achieve great results. By understanding your business needs we draw expertise from across the company to create bespoke teams that can successfully design and implement strategies that meet your objectives and deliver real value. With over 170 people specialising in sports marketing, content creation and distribution, events and media our knowledge, experience and network drawn from decades of working in sport allows us to provide our clients with the very best advice and services across International markets.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Aurora BioScience is a young and vibrant medical device distribution company based in Sydney, Australia. Our growing product range includes some of the world's most novel products and cutting edge medical solutions. Our specialty networks extend across metropolitan and regional areas in all Australian states and throughout New Zealand.

Caliper, A PerkinElmer Company, is a research tools company engaged in the sale of innovative and enabling products, services, and systems to academic, government and and biotech/pharmaceutical researchers worldwide. It provides molecular solutions for preclinical imaging as well as in vitro research and diagnostics. The company's products and services, assembled from a portfolio of microfluidics, automation, liquid handling, and molecular imaging technologies, addresses various pre-clinical drug discovery and development bottlenecks. Its products and services include LabChip drug discovery, profiling and separations systems; IVIS noninvasive imaging systems, reagents and animal models; and automation and liquid handling systems. The company also offers contract research and transgenic animal services, drug discovery and development services, product support, and validation services. Caliper Life Sciences sells its products directly to customers, as well as through its network of distributors. The company was founded in 1995 and is headquartered in Hopkinton, Massachusetts.

Formerly based in South San Francisco, California, Onyx Pharmaceuticals was engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Amgen acquired Onyx Pharmaceuticals in 2013. See our Community Guidelines: bit.ly/smcgl

The 6th USA Science & Engineering Festival, the largest and only national science festival, features nationwide contests and school programs, including our popular 'Nifty Fifty'​ science speaker program and X-STEM Symposium. The Festival will culminate in a Grand Finale Expo in the Spring of 2020, with Sneak Peek Friday kicking off the weekend. More than 365K+ attendees will celebrate science at the Expo, and engage in activities with some of the biggest names in STEM, hear stories of inspiration and courage, and rock out to science during our incredible stage show performances. Get involved by exhibiting, sponsoring, volunteering or attending!

We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.

San Diego-based Sapphire Energy is pioneering an approach that takes two very old processes and synthesizes them into one very new opportunity. Farming and algae have been around for most of human existence, but the two have not been paired in any significant way to bring leverage the positive effects on one another. Sapphire’s products and processes in this category differ significantly from others because they are made solely from photosynthetic microorganisms (algae and cyanobacteria), using sunlight and CO2 as their feedstock; are not dependent on food crops or valuable farmland; do not use potable water; do not result in biodiesel or ethanol; are compatible with existing infrastructure; and are low carbon, renewable and scalable. Sapphire has an R&D facility in Las Cruces, New Mexico, and has been operating a 300-acre facility continuously since May 1, 2012. Learn More at www.sapphireenergy.com Like us on Facebook https://www.facebook.com/Sapphireenergy Follow us on twitter https://twitter.com/SapphireEnergy Watch our videos https://www.youtube.com/user/SapphireEnergyVideo